Latest news

Adalvo is pleased to announce oursuccessful DCP submission for Adapalene + Benzoyl Peroxide Gel. This product has been developed in collaboration with one of our strategic partners, based on the reference...

Adalvo are pleased to announce our successful DCP submission for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray. The product has been developed...

Adalvo is thrilled to have successfully executed Dimethyl Fumarate 120/240mg Capsules in Mexico, with our esteemed partners, Corne. This successful execution marks a significant milestone in Adalvo's commitment to delivering competitive pharmaceutical solutions around...

Adalvo is delighted to highlight the expansion of its portfolio with the well-established Dimetindene Gel 0.1% (1mg/g). This product has been developed based on the reference brand Fenistil Gel, and is intended...

Adalvo is pleased to announce that the successful Pivotal BE Study for Brivaracetam Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for January 2024. Brivaracetam Film Coated...

We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets. This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients. Our Desogestrel+Ethinylestradiol...

Adalvo is pleased to announce that the successful Pivotal BE Study for Afatinib Film-Coated Tablets has been completed and we are now preparing our dossier submission which is scheduled for November 2023. Our...

We are pleased to announce our successful DCP submission for Mirabegron prolonged release tablets.  This product has been developed in collaboration with one of our strategic partners, based on the reference brand, Betmiga prolonged release...

Adalvo is pleased to announce a new collaboration with Stendhal, a Mexican pharmaceutical company that provides innovative therapies to improve the quality of life of patients, with presence in Mexico...

In our pursuit of being at the forefront of innovation, we are delighted to share the news of our second successful DCP closure for Desmopressin. While the demand has been...

Adalvo and SteinCares are pleased to announce the extension of their long-term strategic collaboration in Latin America. The companies have recently signed a basket deal for five products to be...

Adalvo is delighted to announce the successful DCP submission of our Dydrogesterone 10mg tablets. Adalvo takes great pride in being amongst the first wave of filers in the EU, with...

We are pleased to announce the successfulDCP approval for Eribulin solution for injection, 0.44mg/ml. As of today, there are no generic MA’s granted for this product. We will now progress with...

Adalvo is excited to announce that we have successfully completed our Pivotal BE program for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray.

Adalvo and EQL Pharma have established a formidable partnership, entering into a strategic licensing agreement for Mellozzan® (with active ingredient melatonin). This collaboration grants Adalvo exclusive rights to register, commercialize,...

Adalvo is excited to announce the launch of Solifenacin + Tamsulosin in Europe. Our niche product is a fully bioequivalent version of Vesomni MR Tablets, 6mg/0.4mg, indicated in the treatment...

Adalvo is pleased to announce the successful DCP Submission for Drospirenone + Ethinylestradiol. Drospirenone + Ethinylestradiol has been developed, in collaboration with one of our strategic partners, based on the...

Reference is made to the recent decision by the Federal Patent Court, where the Betmiga (Mirabegron) ’427 patent and its SPC, was declared invalid with effect, for Germany. This decision...

Adalvo is excited to announce our expansion within the US market through a new strategic distribution and collaboration agreement with Sandoz.

Adalvo is thrilled to announce that we have successfully completed our Pivotal BE program for Empagliflozin 25mg film-coated tablets. This product has been developed in collaboration with one of our...

Adalvo is pleased to announce the successful Pivotal BE Study for Riociguat 2.5mg Film Coated Tablets. With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of...